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The NHMRC Clinical Trials Centre (CTC) at the University of Sydney runs large 
multicentre investigator-initiated clinical trials, takes part in trials of national and 
international collaborative trial groups and contributes expertise to trials run by others.  
It also:
•	 takes a lead in proposing new directions for trial research in Australia, particularly  
with regard to integrating clinical trials with national policy and clinical practice
•	 leads, coordinates and participates in national and international research 
collaborations
•	 undertakes methodological research in relation to clinical trials and biostatistics
•	 reviews and synthesises evidence from completed trials, and is at the forefront of 
developments in methods, such as prospective meta-analysis
•	 advises on trial design and operation, and randomises patients and analyses data for 
other groups conducting trials
•	 offers postgraduate supervision in all of these areas
•	 offers a postgraduate program in clinical trials research by distance education
•	 runs short courses in the design and conduct of clinical trials as part of its undertaking 
to train people for Australian medical research
Core funding is provided by the National Health and Medical Research Council (NHMRC), 
and specific projects are funded by government, public and private institutions and the 
pharmaceutical industry. 
The CTC is at two sites in Camperdown in inner Sydney — the Medical Foundation 
Building on Parramatta Road and on Mallett Street.
This report covers the CTC’s achievements for 2011.
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CTC executive
For more than 20 years now, the Clinical Trials Centre 
has been working to improve health outcomes, 
practice and policy through clinical trials research. 
Broadly, our activities include undertaking trials, trial 
methodology, evaluating and combining evidence, 
coordinating and planning translational studies, and 
clinical trials education and training.
The outstanding success of our research effort has 
been built on working effectively with national and 
international collaborative groups, networks and 
partners.
In 2011, the CTC and its collaborators at the 
Boden Institute of Obesity, Nutrition, Exercise and 
Eating Disorders (BIONE) and Macquarie University 
were awarded a five-year program grant from the 
NHMRC, to start in 2013. Significantly, this reflects 
our view of the importance of methodological 
research and also that our core work goes beyond 
the CTC and extends our reach to a broader picture 
of diabetes that includes obesity. These synergistic 
collaborations will foster growth and development in 
each area.
Integrating expertise from BIONE and CTC will 
help us to establish new clinical trials addressing 
important questions, particularly in obesity, and the 
metabolic aspects of diabetes and cardiovascular 
diseases. The joint initiatives will result in shared 
intellectual understanding of the diseases and the 
clinical trials process and its outcomes.
Collaboration and integration are key components 
underpinning our whole research program. 
Modern clinical research projects rely increasingly 
on contributions from people with various skills, 
knowledge and perspectives, and work at the CTC is 
consistent with the worldwide trend. In 2011, over 
90% of our publications involved cooperation with 
other organisations, and 30% of the author groups 
were multinational.
Our research collaborations, which include 
groupings within the CTC, across Australia and 
internationally, lead to better coordination of 
research projects, leverage the different contributions 
of experts in various fields of research and thus 
maximise the research effort. The exchange of 
ideas and the combined intellectual input of people 
working on a common cause also leads to new 
research questions and solutions.
Our trials are investigator initiated; that is, 
they arise from the experience of patients or their 
doctors perceiving a need for more evidence about 
particular treatments. Transforming a good idea into 
a completed trial is a group effort. The CTC takes 
leading roles to various degrees at various stages, 
from concept development through trial design, 
acquiring funding, trial conduct, data analysis, and 
publication of results.
For example, cancer clinical research in Australia 
relies on investigators across the country who 
conceive, initiate and conduct trials in areas of 
need. We work closely with eight Australian cancer 
cooperative trial groups. These, in turn, have working 
relationships with 14 international cancer groups. 
They currently have nearly 50 trials in recruitment or 
in follow-up, with many more in development.
Directors’ report         
CTC operations and research are led by the Executive: John Simes, director; Tony Keech, deputy director; Wendy Hague, clinical trials 
program director; and Kim Russell-Cooper, general manager. 
Professor John Simes is the foundation director of the CTC and represents the CTC on many national and international 
committees. He has for many years championed the need for evidence-based clinical research. 
Professor Anthony Keech is Professor of Medicine, Cardiology and Epidemiology at the University of Sydney. He is chairman of 
the international FIELD study on heart disease and diabetes and directs the CTC’s research program.
Dr Wendy Hague is primarily responsible for the successful conduct of the CTC’s large-scale, multicentre clinical trials and ensuring 
that trials systems, procedures and methods are of the highest standard. 
Kim Russell-Cooper works with the CTC executive, managers and research staff to improve the business process in the areas of 
clinical trial research governance, risk assessment, financial planning, management and reporting.
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2011 was notable for new evidence on neonatal 
therapies. The INIS trial showed that intravenous 
immunoglobulin used with antibiotics for neonatal 
infection did not have benefits. There had been 
uncertainty about whether this therapy was effective. 
The new findings will allow hospitals to avoid an 
expensive treatment. The MAPPiNO international 
meta-analysis showed that, despite some earlier 
positive evidence, nitric oxide did not improve lung 
function in premature infants. Interestingly, both 
of these studies showed that a new treatment did 
not work, but this knowledge is just as important to 
clinical practice as a positive result would be.
In the work we do with others, trials are central, 
but we now look to the full range of the clinical 
research pathway, ‘from bench to bedside’. In 2011, 
we played a part in a significant development for 
cancer research in NSW—the founding of Sydney 
Catalyst, which we expect will pave the way for new 
and exciting developments in oncology. Directed 
by John Simes, Sydney Catalyst brings together 
outstanding teams of researchers and clinicians 
from leading NSW institutions with the ability to 
undertake the full spectrum of cancer research from 
basic science to implementing evidence in practice. 
The secretariat is based at the CTC.
Translating the evidence from clinical trials into 
better practice is a major focus of the CTC. We 
evaluate the evidence, combine the evidence in 
systematic reviews, and translate the evidence into 
guidelines and protocols, with the aim of improving 
health in Australia and elsewhere. The ANZ Clinical 
Trials Registry, based at the CTC, which lists current 
trials in Australia, New Zealand and elsewhere, is an 
important link in the process. It is one of the primary 
international trials registries, whose records can be 
accessed by anyone. The ANZCTR is helping improve 
the efficiency and value of clinical trials research 
undertaken in Australia by enabling researchers and 
policy makers to identify potential gaps where more 
research is needed. The trial registry is also alerting 
patients and their doctors to available trials, easing 
their access to the best treatment and improving 
participation in trials.
At the CTC, we aim to share our knowledge. 2011 
was the first year of our new postgraduate course 
in clinical trials research at the University of Sydney. 
It was developed in response to a need for formal 
qualifications in this area, and is equipping students 
to design and lead clinical trials. Australian and 
overseas aspiring triallists have shown considerable 
interest in the course, with 23 people enrolling in its 
inaugural year. The blueprint for the course and its 
implementation evolved out of the long experience 
of the CTC in all aspects of trials, particularly 
methodology, and the Biostatistics Collaboration 
of Australia in delivering successful postgraduate 
education by distance means.
Our plans for the future include continuing our 
efforts to make clinical trials an integral part of 
routine health care. We will also maintain and build 
our global collaborative ties with other research 
networks, universities, government, and industry, to 
answer important clinical questions in new therapy 
areas. These plans are on track, thanks to the efforts 
of our staff, our collaborating investigators and 
our funders from government, nongovernment 
organisations and industry.
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not just trials but the full spectrum of research:  
laboratory, clinical and implementation
Traditionally, laboratory discoveries, such as new 
drugs, have been developed through human clinical 
trials, accumulation of evidence, clinical guidelines, 
and then implemention in clinical practice, a serial 
operation that has been estimated to take up 
to 20 years. The CTC, in conducting trials of new 
treatments, has been at the centre of this process, 
but increasingly, in its translational research, has 
been part of efforts to condense the gap between 
a new treatment and its eventual use to improve 
patients’ survival and quality of life.
Translational research aims to make medical 
research findings usable and applicable to patients 
with minimal delay, by integrating the traditional 
stages of research in a single program. The CTC’s 
translational research projects integrate laboratory 
and clinical research or explore ways of applying 
evidence-based medicine, recommendations or 
guidelines to clinical practice. In 2011, the CTC and 
its collaborators continued to develop and conduct 
translational programs in the CTC’s main areas of 
expertise: cardiovascular disease and cancer. 
Most CTC trials now include an option for patients 
to consent to their biological samples (such as tissue 
and blood) being used in research. Biomarkers 
detected in these biological samples are studied for 
their potential utility, for example, as a diagnostic 
test for a disease. They are also used as markers 
that predict response to treatment or susceptibility 
to side-effects, a step on the way to personalising 
treatments for individual patients. This information 
may also be used to assess the eligibility of patients 
for new trials.
Biospecimens are stored in biobanks for the 
future, because knowledge and technology are 
developing rapidly, and new research ideas may 
come about during the course of a trial running over 
several years. 
Extensive new laboratory-based studies in heart 
disease and diabetes have been initiated on the basis 
of biological data derived from two large completed 
heart disease prevention trials, LIPID (p. 5) and 
FIELD (p. 8).
In oncology, Sydney Catalyst: the Translational 
Cancer Research Centre of Central Sydney and 
Regional NSW (p. 6) is a major initiative for  
New South Wales. The CTC is contributing to its 
program.
A collaboration comprising researchers from 
the University of Queensland, the Peter MacCallum 
Cancer Centre, the Garvan Institute and the CTC 
were awarded an NHMRC Project Grant to embark 
on GAP-T, a study of bioimaging and molecular 
biomarkers to guide treatment of patients receiving 
preoperative chemotherapy for pancreas cancer. 
Two new research institutions joined the 
EVERSUN trial (p. 12) 
in blood biomarker 
studies of renal-cell 
cancer patients: the 
Kolling Institute at the 
University of Sydney and 
the Australian Prostate 
Cancer Research 
Centre based at the 
Institute of Health and 
Biomedical Innovation, 
Queensland University 
of Technology.
BASIC 
SCIENCES
CLINICAL 
RESEARCH
CLINICAL 
PRACTICE
IMPLEMENTATION 
RESEARCH
REFINEMENT 
(BIOMARKERS)
INTERPRETING 
EVIDENCE
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Translational research
The LIPID australasian 
collaboration extended 
in biomarker studies
The LIPID study was the first major 
multicentre clinical trial conducted 
by the CTC. It was one of the 
largest clinical trials undertaken 
in Australia, involving over 9000 
patients from 87 hospitals in 
Australia and New Zealand, and 
a team of biostatisticians, trial 
coordinators and data managers 
at the CTC. 
The finding from LIPID that 
the study drug, pravastatin, 
significantly reduced prespecified 
cardiovascular events and 
mortality led to new Australian 
and international guidelines. 
Now, 15 years after the close 
of the trial, patients are still 
being followed up for long-term 
effects of their trial treatment via 
questionnaires collecting data on 
their medication for cardiovascular 
disease and their smoking and 
diabetes status. Data are available 
for about 95% of the surviving 
cohort. Trial researchers have also 
obtained data from linkage with 
death and cancer registers, and for 
a subset of patients, from hospital 
admission data. 
The LIPID investigators had 
the foresight to obtain consent 
from patients for their blood 
to be used in future analysis. 
Blood collections were repeated 
at intervals over the course of 
the trial. These samples are 
now providing important new 
biological data which can be 
related to individual risk of 
cardiovascular events and the 
effects of pravastatin treatment 
on risk. The original group of 
investigators has expanded to 
include scientists in Germany, 
where blood samples have been 
analysed for biomarkers for 
cardiovascular disease. 
The collaboration now focuses 
on relating levels and changes 
of various blood components to 
trial outcomes. This involves work 
by the laboratory scientists and 
local biostatisticians, who have 
developed new models of risk and 
prediction. 
Preliminary results of these 
studies were presented at the 
meeting of the American Heart 
Association in November. It 
was found that adding some 
biomarker levels (brain natriuretic 
protein, cystatin C, D-dimer and 
troponin I) to a conventional risk 
model significantly improved 
the estimation of the risk of a 
recurrent heart attack. Patients 
above the top quartile of risk were 
identified as priority candidates for 
more intensive treatment.
LIPID StuDy gRouP
Professor andrew Tonkin,  
Monash University,  
Melbourne (chair)
Professor Stefan Blankenberg, 
University Heart Centre, Hamburg
associate Professor David 
Colquhoun, Greenslopes Hospital, 
Brisbane
Professor Paul Glasziou,  
Bond University, Gold Coast
Dr Wendy Hague, CTC
Dr David Hunt, Melbourne
Professor anthony Keech, CTC
Ms adrienne Kirby, CTC
Professor Paul nestel, Baker IDI, 
Melbourne
Professor John Simes, CTC
associate Professor David Sullivan, 
Royal Prince alfred Hospital, 
Sydney
Professor Peter Thompson,  
Sir Charles Gairdner Hospital, 
Perth
Professor Malcolm West,  
University of Queensland
Professor Harvey White,  
auckland City Hospital
TEK IMAGE/SCIENCE PHOTO LIBRARY
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WHo’S WHo At SyDney CAtALySt
SCIentIfIC ADvISoRy CommIttee
Professor John Simes, program director
Professor Michael Boyer (medical director, Chris 
o'Brien Lifehouse, Royal Prince alfred Hospital)
Professor Mathew Vadas (executive director, 
Centenary Institute of Cancer Medicine & Cell 
Biology, University of Sydney)
Professor Rob Sutherland (director, Kinghorn 
Cancer Centre, Garvan Institute of Medical 
Research)
Professor Michael Solomon (director, Surgical 
outcomes Research Centre (SouRCe), University 
of Sydney)
Professor Phyllis Butow (director, Centre for 
Medical Psychology and Evidence-based Decision-
making (CeMPED), University of Sydney
Scientific advisory Committee, 2011
goveRnIng CounCIL membeRS
Professor andrew Biankin (head, Pancreatic 
Cancer Research, Garvan Institute of Medical 
Research)
Professor Jane Young (Cancer Epidemiology, 
School of Public Health, University of Sydney)
associate Professor Martin Stockler, (oncology 
program co-director,)
Dr Sonia Yip (senior translational research fellow, 
Sydney Catalyst)
Mr John newsom (Cancer Voices australia)
Sydney Catalyst: a CTC collaboration
In 2011, Sydney Catalyst: the Translational Cancer 
Research Centre of Central Sydney and Regional 
NSW was established with funding from the Cancer 
Institute NSW. The CTC is one of the collaborators in 
this program, and Professor John Simes, CTC director, 
is to be responsible for its leadership and direction.
In Australia, many millions of dollars, and 
worldwide, billions, are spent on cancer research. 
Usually, many years pass before laboratory 
discoveries reach clinical practice. Novel therapies 
must be tested in various phases of clinical trials and 
the results integrated into evidence that can be used 
in treatment guidelines and adopted by clinicians.
Translating new knowledge into improved 
outcomes quickly requires cooperation and 
collaboration among many people and institutions 
with specialised expertise. 
Sydney Catalyst is a consortium covering the full 
spectrum of cancer research and clinical practice: 
basic biosciences, molecular biomarker discovery, 
descriptive research, clinical trials, psychosocial 
research and implementation research of best 
evidence-based care into practice. It brings together 
outstanding teams of researchers and clinicians with 
the aim of improving cancer health outcomes for 
people affected by cancer. It exists as a virtual centre, 
the inaugural Sydney Catalyst planning meeting for 
members at the university of Sydney in october
Translational research
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connecting researchers from a range of different 
disciplines and groups to work together to achieve 
specific objectives and goals. The consortium aims to 
ensure that discoveries are rapidly implemented into 
evidence-based practice.
The research falls into two areas, theme 1 (T1) and 
theme 2 (T2):
T1: developing therapeutic strategies using patient 
and cancer biomarkers and linking the biosciences, 
clinical trials and individualised care.
T2: increasing the use of evidence-based care in 
practice, for example, by building more effective 
models for providing effective cancer care and closing 
the gap between the evidence and practice.
Specific goals for the near future are to:
•	 build partnerships and facilitate and increase 
collaboration.
•	 develop and undertake major research initiatives 
across the spectrum of cancer research, including 
laboratory research, clinical research and 
implementation research. 
•	 increase expertise, career development 
and research capacity through professional 
development and educational opportunities for 
both clinicians and researchers.
The consortium has established the governance 
and organisational structure needed to help support 
members to achieve its goals. 
John Simes, director, and Danielle miller, research manager, 
Sydney Catalyst
membeR gRouPS AnD HoSPItALS, 2011
asbestos Diseases Research Institute (aDRI)
anZaC Research Institute (includes Dendritic Cell 
Biology and Therapeutics Group)
Bathurst Base Hospital
Cancer researchers from University of Sydney (includes 
Cancer Epidemiology and Services Research group 
(CESR), Cancer nursing Research Unit (based at SCC), 
the Centre for Medical Psychology & Evidence-based 
Decision-making (CeMPED), nHMRC Clinical Trials 
Centre, Surgical outcomes Research Centre (SouRCe), 
Institute of Medical Physics (School of Physics))
Canterbury Hospital
Centenary Institute
Coffs Harbour Base Hospital
Concord Repatriation General Hospital
Cunningham Centre for Palliative Care,  
St. Vincent's Hospital
Dubbo Base Hospital
Melanoma Institute australia
north Coast Cancer Institute,  
Coffs Harbour Hospital
orange Hospital
Royal Prince alfred (RPa) Hospital 
St. Vincent's Hospital  
(includes the Sacred Heart Hospice)
Sydney Cancer Centre/the Chris o'Brien Lifehouse at 
RPa (includes Department of Radiation oncology)
The Kinghorn Cancer Centre, Garvan Institute
Wagga Wagga Base Hospital
InveStIgAtoR gRouPS
Current collaborating partner groups include:
aGITG, aLTG, anZBCTG, anZGoG, anZUP, CoGno, 
PC4, and PoCoG
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Unlocking genetic factors predicting type 2 diabetes 
complications
Diabetes and its complications have been linked to various genes through 
genome-wide association studies over the past decade. 
New CTC research is identifying genetic contributions to the 
complications of diabetes; these include heart disease, stroke, eye disease 
and kidney disease. Another research question is whether genetic ageing 
is accelerated by diabetes. 
Scientists are analysing single-nucleotide polymorphisms (SNPs) from 
targeted areas on the chromosomes of control subjects without diabetes 
and 5000 patients from the completed FIELD trial (p. 16). Biostatisticians 
at the CTC will use the eventually very large dataset to analyse the genetic 
patterns in relation to diabetes risk and complications and to resolve 
other questions about diabetes. The answers may be a step in the process 
of personalising clinical medicine.
Patients in the FIELD trial provided blood samples and gave consent 
for their blood to be used in scientific studies to benefit future diabetes 
patients. The blood has been stored for analysis at the FIELD study 
laboratories in Sydney and Adelaide. 
A large project like this demands the skill and knowledge of a diverse 
group of people. Professor Tony Keech from the CTC is chairing the 
group, just as he has chaired the FIELD trial over the past 10 years. Other 
members of the team have expertise in the biochemical basis of diabetes, 
atherosclerosis, genetics and diabetes, and the relationships among 
diabetes, chromosomes and ageing.
Alicia Jenkins, Anand Hardikar, Surya Sutanto, Stephen twigg, Anthony Keech, 
Susan mcLennan, Wilson Wong
CoLLAboRAtIonS 
Professor James Best,  
University of Melbourne
Professor Stephan Blankenberg,  
University Heart Centre, Hamburg
Dr andrzej Januszweski,  
University of Melbourne
Professor alicia Jenkins,  
University of Melbourne
Professor Markku Laakso,  
University of Kuopio
associate Professor Susan McLennan, 
Sydney Medical School
Professor John Simes, CTC
Dr Helen Speirs,  
University of new South Wales
Professor Stephen Twigg,  
University of Sydney
Professor Russell Scott,  
Christchurch Hospital
Translational research
Translational research
QUaLITY oF LIFE anD SURVIVaL In CanCER
Clinical trials in oncology: they need australia-wide networks of 
people with diverse but complementary skills
Because many research questions relate to relatively 
rare events, high-quality trials require large numbers 
of participants, recruited from many hospital centres. 
In Australia, multicentre trials in oncology are made 
possible by national networks of investigators, 
each specialising in a tumour site or system. These 
investigators propose research questions, explore the 
feasibility of answering each research question with a 
trial, and then develop the concept into a trial. 
Members of these collaborative groups represent 
the disciplines involved in clinical research and 
treatment, including statisticians, data managers, 
research nurses, trial coordinators, medical 
oncologists, surgeons, radiation oncologists, 
scientists and pathologists. Each project needs the 
expertise of many people through the process of 
protocol development, funding, ethics approval, site 
selection, recruitment, data collection, analysis and 
publication.
Most of the recent advances in cancer care in 
Australia can be attributed to collaborative group 
trials. Recognition of this has resulted in national 
efforts to build the capacity of the groups, to develop 
common infrastructure and to improve the efficiency 
of their activities, mainly with funds from Cancer 
Australia and the Cancer Institute NSW.
The CTC works collaboratively as sponsor, 
coordinating centre or supporting consultant with 
five of these specialised oncology research groups:
•	 Australasian Gastro-Intestinal Trials Group 
(AGITG)
•	 Australia New Zealand Gynaecological Oncology 
Group (ANZGOG)
•	 Australasian Lung Cancer Trials Group (ALTG)
•	 Australian and New Zealand Urogenital and 
Prostate Cancer Trials Group (ANZUP)
•	 Cooperative Trials Group for Neuro-Oncology 
(COGNO)
and the Royal Australasian College of Surgeons.
The CTC also provides randomisation and 
statistical support to the Australia & New Zealand 
Breast Cancer Trials Group (ANZ BCTG) and trial 
concept development support to the Primary Care 
Cooperative Cancer Clinical Trials Group (PC4).
CTC collaboration with the the Royal australasian 
College of Surgeons in trials of treatment early  
breast cancer
The Sentinel Node versus Axillary Clearance (SNAC) trial was the first, large, 
Australasian prospective assessment of the risk of lymphoedema after surgery 
for early breast cancer. The trial compared sentinel node biopsy of selected 
lymph nodes with clearance of axillary nodes in women with tumours smaller 
than 3 cm. Short-term results showed that arm swelling was less in the group 
having only sentinel node biopsy. Both treatment groups had  moderate 
limitations in arm movement over the first 6 months, which then recovered to 
near normal levels. The results showed that for women with small tumours, sentinel node biopsy was a viable 
alternative to axillary clearance. The patients are being followed up so that long-term effects can be measured. 
Outcomes at 3 years will shortly be published.
In  SNAC 2, the investigators are recruiting women with large or multiple tumours in a more extensive trial 
with similar questions, which will allow any differences in subgroups of women to be analysed.
breast cancer cell (scanning 
electron micrograph)
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Gynaecological cancer trials in australia
The Australia New Zealand 
Gynaecological Oncology 
Group (ANZGOG), a network 
of investigators, supports 
collaborative research to improve 
outcomes for women with 
gynaecological tumours, that is, 
all cancers involving the female 
reproductive system. The CTC 
ANZGOG team collaborates with 
ANZGOG in developing new 
concepts into functioning trials 
and obtaining funding. Together 
they encourage clinicians and 
researchers to participate and 
publish results widely. Nine trials 
are recruiting or in follow-up and 
more are in development.
ANZGOG was formed in 2000 
and soon after that allied itself 
with the Gynecological Oncology 
Group (GOG) in the United States 
and also became a member of the 
Gynecological Cancer Intergroup 
(GCIG).
outbACK CeRvIx  
CAnCeR tRIAL
Outback is a flagship study for 
ANZGOG. It is investigating 
the effect of adding further 
chemotherapy to standard 
chemoradiation for patients 
with high-risk cervix cancer. 
This is widely acknowledged 
to be the most important 
unanswered question in cervix 
cancer treatment. The concept 
was first proposed by Associate 
Professor Linda Mileshkin at 
the 2008 Annual Scientific 
Meeting. She has championed 
the concept ever since and, 
with the efforts of the team 
at the CTC, has secured 
funding from the National 
Cancer Institute to support 
the participation of GOG and 
another US cooperative group, 
RTOG, so that American 
patients can join the trial. 
Thirteen sites in Australia-New 
Zealand and 15 in the US have 
now been activated.
CeRvIx CAnCeR  
ReSeARCH netWoRK
Outback is also the first study 
for the Cervix Cancer Research 
Network, which aims to help 
institutions in developing 
countries participate in high-
quality academic clinical trials.  
Dr Julie Martyn, ANZGOG 
manager, has conducted site 
visits in India and Thailand 
to assess their capacity to 
participate in trials such as 
Outback.
Quality of life and survival in cancer
Linda mileshkin,  
chair of the outback study
GABRIELLE VOINOT/LOOK AT SCIENCE/SCIENCE PHOTO LIBRARY
Translational research
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Clinical trials to find better treatments for people with gastrointestinal cancers
The Australasian Gastro-Intestinal Trials Group is a 
not-for-profit company that facilitates clinical trial 
research into cancers of the oesophagus, stomach. 
liver, gall bladder, pancreas and bowel. Members can 
propose new concepts for trials, which may then be 
developed by the group in collaboration with the 
CTC, the coordinating and statistical centre for the 
AGITG since its inception in 1991. Over 20 years, the 
collaboration has produced 51 peer-reviewed journal 
articles and over 100 conference presentations.
The CTC collaborates with various international 
cooperative groups, allowing patients from the 
Australasian region to participate in clinical trials of 
international significance. These include the National 
Cancer Institute of Canada Clinical Trials Group (NCIC 
CTG), the European Organisation for Research and 
Treatment of Cancer (EORTC), European Study 
Group for Pancreatic Cancer (ESPAC), Oxford 
Clinical Trials Office, Oxford University (OCTO) , 
Pan-European Trials in Alimentary Tract Cancer 
(PETACC), the UK Medical Research Council (MRC), 
Cancer Clinical Trials Unit Scotland (CACTUS), 
Groupe Coopérateur Multidisciplinarie en Oncologie 
(GERCOR), the Trans-Tasman Radiation Oncology 
Group (TROG), and in the United States, the Eastern 
Cooperative Oncology Group (ECOG) and the the 
National Surgical Adjuvant Breast and Bowel Project 
(NSABP). 
 The trials are not commercially driven and 
aim to improve the treatment of people with 
gastrointestinal cancers. In 2011, work from the 
AGITG and CTC, with their collaborators, generated 
new results from ABC, C07, CO.17, Da VINCI, ESPAC3, 
GOFURTGO, IG9401, MAX, and SCOT trials. 
Quality of life and urvival in cancer
John Zalcberg, AgItg chair (with colleagues), chairing the AgItg annual general meeting
Scanning electron 
micrograph of a 
colorectal cancer 
cell dividing
STEVE GSHMEISSNER/SCIENCE PHOTO LIBRARY
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Jay griffiths, Amy boland, Jennifer thompson,  
oncology staff working with AnZuP
Urogenital cancers (anZUP trials)
Research in urogenital and prostate cancers is 
carried out in collaboration with the Australian and 
New Zealand Urogenital and Prostate Cancer Trials 
Group (ANZUP). ANZUP was formed in 2008 by 
amalgamation of the Australian and New Zealand 
Germ Cell Trials Group and the Australian Prostate 
and Urogenital Cancer Group. 
ANZUP aims to minimise the effect of prostate 
and other urogenital cancers on the community 
in terms of survival, incidence and quality of life, 
through research and education and by providing 
patients and carers with support. 
In 2011, the group presented results at 
international oncology conferences, for Accelerated 
BEP, a study of the feasibility and tolerability of a 
dose-dense treatment regimen for germ cell cancer, 
and EVERSUN, a trial of the effect of alternating 
two drugs: one an anti-angiogenic therapy, the 
other an anti-mTOR targeted therapy (sunitinib or 
everolimus) in patients with renal cell cancer. 
Lung cancer (aLTG trials)
Lung cancer is a common cancer with a poor 
prognosis, making it the leading cause of cancer 
death in both men and women in Australia. It 
has been listed by the Australian Government as 
a disease causing a significant burden in terms of 
morbidity, mortality and health care costs.
The CTC undertakes trials in lung cancer in 
collaboration with the Australasian Lung Cancer 
Trials Group (ALTG), a multidisciplinary organisation 
dedicated to reducing the incidence, morbidity 
and mortality of lung and thoracic cancer and 
improving the quality of life of lung and thoracic 
cancer patients in Australia and New Zealand. The 
group has several trials near completion, in progress 
and in development. In 2011, the group presented 
results from the Maintenance Thalidomide in 
Mesothelioma (MATES) trial, a collaboration with 
Dutch investigators which examined the effect on 
survival of adding thalidomide to maintenance 
chemotherapy. These preliminary results showed 
that thalidomide treatment was safe, but survival 
was not significantly longer. Secondary studies on 
patient preferences and survival estimation arising 
from ALTG trials were also presented.
Tumours of the brain and nervous 
system (CoGno trials)
The CTC is a partner in the trials of the Cooperative 
Trials Group for Neuro-Oncology (COGNO), an 
Australian organisation concerned with clinical trials 
to improve outcomes for people affected by brain 
tumours. Members are researchers and clinicians 
involved in various disciplines that touch on this 
area. 
Trials can be evaluations of current therapies, 
new treatments or supportive interventions for 
brain tumours. Beyond the trials, the group aims to 
promote integrated laboratory substudies, and also 
to engage members of the medical and scientific 
community who might participate in the research 
process. The group is currently conducting a major 
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Brain cancers are not common; only 7 in 100,000 people in australia 
are diagnosed with a brain tumour each year, but the emotional and 
economic burden for patients and their families is great. The average 
person-years of life lost has been estimated at 12 years per patient, 
much higher than the 3 years average for all cancers. 
about half of the brain tumours diagnosed in australia are 
glioblastoma multiforme, an aggressive disease which is resistant to 
most chemotherapy. Radiotherapy plus a period of temozolomide 
chemotherapy results in some improvement in survival, but the 
blood-brain barrier is an obstacle to delivery of the drug to the 
tumour. Better treatment for this cancer is keenly sought.
CoGno researchers conducted a phase 2 trial adding pegylated 
liposomal doxorubicin (PLD) to the standard treatment. Doxorubicin 
is known to kill glioma cells, and its formulation as PLD allows it 
to cross the blood-brain barrier relatively effectively. In this trial, 
survival did not increase significantly, although the trial showed that 
the combination of the two chemotherapy drugs was well tolerated 
by patients.
ananda et al. Journal of Clinical Neuroscience
Coloured three-dimensional diffusion 
tensor imaging scan in top view 
through the brain, showing a 
glioblastoma brain cancer tumour 
(light blue) among the normal 
orientation of bundles of white  
matter nerve fibres
Kate Sawkins, Alan Lucas, bhagwant 
Sekhon, bea tomes and trevor france, 
supporting brain cancer trials at the CtC 
(Ann Livingstone on leave)
Quality of life and survival in cancer
contribution to an international study and two locally developed trials. In 2011, its trial of 
doxorubicin added to temozolomide for glioblastoma multiforme was completed and results 
published.
COGNO was formed in 2007 and is now firmly established and flourishing. Each year, a 
national scientific meeting has given members the opportunity to plan, to propose new research 
questions, and to learn about current research. 
In 2011, COGNO received two important grants from Cancer Australia, one to fund the group 
and the other for its CATNON study.
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Highlights of  
published research
PReDICtIon AnD PRognoSIS
Can CA-125 predict response 
to treatment?
Cancer antigen 125 (CA-125), is 
an indicator of tumour activity. 
When patients are being treated 
with chemotherapy for ovarian 
cancer, if the level of CA-125 goes 
down, the doctor may assume 
that the chemotherapy is having 
an effect. However, some have 
questioned whether early changes 
in the level of CA-125 in response 
to chemotherapy predict the 
patient’s condition several months 
down the track. This was tested 
in a study done by the CALYPSO 
international trial group, based 
on statistical analysis led by CTC 
researchers. They found that the 
level of CA-125 was not a good 
predictor of the effect of treatment 
and recommended that doctors 
should not rely on this as an 
indication for ceasing treatment.
The CALYPSO trial was a 
Gynecologic Cancer InterGroup 
trial, led by GINECO in France, 
with participating researchers 
Belgium, Italy, Germany, Denmark, 
and Australia and New Zealand 
(ANZGOG). This secondary study 
was published in the Journal of the 
National Cancer Institute. 
Prognostic nomograms for 
ovarian cancer and breast 
cancer
Patients with advanced ovarian 
cancer are varied, and it has 
been difficult to predict their 
progression-free survival time. 
A tool that predicts the effect of 
platinum-based chemotherapy 
in individual patients has been 
developed and validated (see 
http://roconline.ctc.usyd.edu.
au). It is a step toward improving 
information about prognosis 
for patients and will be useful 
for stratifying patients for future 
clinical trials. The analysis used 
data from the CALYPSO trial. 
Breast cancer patients are 
similarly mixed with respect 
to their characteristics, their 
tumours and their survival times. 
A study used data from three 
large Australian and New Zealand 
trials as a starting point for a 
statistical model for breast cancer 
prognosis. It has the potential to 
improve predictions of survival 
and decisions about treatment for 
patients undergoing anthracycline 
chemotherapy. The nomogram 
derived from the model is available 
online at http://advancedonline.
ctc.usyd.edu.au.
Side-effects of 
chemotherapy can predict 
individual progression-free 
survival
CALYPSO study researchers 
hypothesised that leukopenia and 
sensory neuropathy, common 
toxic side-effects of paclitaxel 
chemotherapy, would reflect 
susceptibility to the treatment, 
and therefore patients with these 
side-effects would also survive 
longer without recurrence of their 
disease. This indeed happened 
during the trial: development 
of neuropathy and increasing 
severity of leukopenia were each 
associated with longer survival 
in patients whose treatment 
included paclitaxel. An implication 
of these findings is that dosages 
of chemotherapy might be 
personalised for individual patients 
on the basis of toxic effects early in 
the treatment regimen.
neW ReSuLtS fRom tHe mAx 
CoLoReCtAL CAnCeR StuDy
The MAX study, an AGITG- and 
CTC-initiated international 
trial completed and published 
in 2010, showed that adding 
bevacizumab to capecitabine 
therapy improved progression-free 
survival of patients with advanced 
colorectal cancer. A recent 
detailed analysis of data from 
the subgroup of patients aged 75 
years or over, published in Annals 
of Oncology, has found that the 
combination of bevacizumab and 
capecitabine is a safe, convenient 
and effective regimen for older 
patients. Older people are often 
not included in clinical trials, so 
their representation in MAX has 
resulted in useful evidence. A 
separate analysis, also published 
in Annals of Oncology, confirmed 
that bevacizumab treatment 
is associated with a modest 
increase in the risk of arterial 
thromboembolism. Further 
substudies, on quality of life 
and psychological issues, are in 
progress.
Quality of life and survival in cancer
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Translational research
Patients differ in their response to biological 
agents such as bevacizumab, depending on the 
genetic status of their tumours. The MAX triallists 
have been examining the effect of the mutation 
status of genes in predicting survival and response 
to treatment. A study published in the Journal of 
Clinical Oncology showed that KRAS and BRAF gene 
mutation status did not affect the patients’ response 
to treatment, but that BRAF gene mutation status 
was prognostic for survival. Additional analyses on 
patients’ tissue samples and linkage of their results 
with trial results are ongoing.
DAvInCI tRIAL
The DaVINCI trial was a comparison of single-
agent (irinotecan) and combination (irinotecan 
and 5-fluorouracil) chemotherapy treatments 
for recurring advanced colorectal cancer. Rates of 
progression-free survival and overall survival slightly 
favoured the combination treatment. Patients on 
combination treatment fared better in terms of 
side-effects. However, there is still a place for the 
single-agent treatment for some patients, depending 
on their vulnerability to certain side-effects and 
their preferences. Full results were published in the 
European Journal of Cancer. 
AWARD foR CAnCeR ReSeARCH
Belinda Kiely, medical oncology research 
fellow, received a Young Investigator Award 
from the Conquer Cancer Foundation of the 
American Society of Clinical Oncology for her 
project, ‘Evaluating an iTool to estimate and 
explain survival time scenarios to people with 
advanced cancer’. 
Belinda and her colleagues developed 
a web-based tool (iTool) to help cancer 
specialists describe three scenarios for 
survival time based on the estimated median 
survival for a group of similar patients. This 
is an extension of her work more generally in 
prognosis, prediction and communication in 
advanced cancers, especially in breast cancer.
oeSoPHAgeAL CAnCeR metA-AnALySIS 
ConfIRmS tHe benefItS of tReAtment 
befoRe oPeRAtIon
Oesophageal carcinoma is treated with surgery, 
usually, but not always, preceded by chemotherapy or 
chemoradiotherapy. A meta-analysis published in The 
Lancet assessed whether these treatments increased 
perioperative mortality and compared the benefits 
of chemotherapy and chemoradiotherapy. Patients 
who had one of these treatments before surgery 
had significantly longer survival than those having 
surgery alone. The benefit of chemoradiotherapy was 
slightly greater than that for chemotherapy alone. 
martin Stockler and belinda Kiely
Quality of life and urvival in cancer
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FIELD data 
answering clinical 
questions about 
diabetes and heart 
disease
The FIELD (Fenofibrate 
Intervention and Event Lowering 
in Diabetes) trial investigated 
the use of fenofibrate to modify 
blood lipids and reduce the risk of 
coronary heart disease in people 
with type 2 diabetes. FIELD was an 
international collaboration among 
investigators from Australia, 
New Zealand and Finland, and 
enrolled 9795 patients. The main 
results were published in 2005, 
but the immense FIELD dataset 
is still being analysed to answer 
questions about diabetes and 
cardiovascular disease.
For example, a substudy 
published in 2011 by Sullivan 
and the FIELD investigators 
examined the relationships 
between the type of glucose-
controlling medication diabetes 
patients were taking when they 
enrolled in the FIELD study, their 
subsequent cardiovascular risk 
and how this was related to their 
lipid-modifying treatment with 
fenofibrate. The study showed 
apparent differences in the risk of 
cardiovascular events associated 
with oral hypoglycemics but 
they were largely abolished by 
adjustment for the severity of 
diabetes and patients’ risk factors.
DIaBETES
cholesterol with high triglycerides 
led to a higher risk. The findings 
were published in Cardiovascular 
Diabetology.
Follow-up of patients in FIELD 
continues, and, as well, blood 
samples from patients are now 
being analysed in a major new 
genetic and molecular studies 
program (p. 8).
Patients with the metabolic 
syndrome—generally high 
blood pressure, a large waist, 
low HDL (good) cholesterol and 
high triglycerides—are more 
likely to develop diabetes and in 
addition may have a higher risk of 
cardiovascular events. The FIELD 
investigators analysed data from 
FIELD and showed that people 
with diabetes who did not have 
the metabolic syndrome had a 
lower risk of cardiovascular events, 
but that high blood pressure 
or a combination of low HDL 
Anthony Keech, chair of the fIeLD management committee
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neonatal collaborations
nEonaTaL CoLLaBoRaTIonS
new findings from neonatal trials
their trials with SUPPORT. The high target showed 
significant increased survival to 36 weeks gestation in 
all infants and in a subgroup of infants enrolled after 
introduction of the revised software. As a result, both 
trials closed recruitment. However, follow-up of all 
infants is continuing and a full follow-up will provide 
evidence on the effects of the oxygen saturation on 
disability and death at 2 years. Substantive reports of 
hospital outcomes will also follow. Until longer-term 
survival and disability are known, it is considered 
prudent not to target the lower range in infants born 
before 28 weeks gestation. The two BOOST II data 
monitoring committees have asked that this advice 
be widely and rapidly disseminated. This advice does 
not represent a standard of care, and may change 
when the primary outcomes of disability-free survival 
are reported in all NeOProM trials (p. 18), by 2014.
Collaboration is more than formal agreements within 
trials and projects. Cooperation among different 
groups across countries and across trials improves 
the efficiency of trials research and aids trialists in 
their decision making, ultimately to deliver the best 
evidence of treatments for patients.
In neonatal research, international cooperation 
among research groups is a way of overcoming two 
obstacles, first, that most neonatal risk is associated 
with prematurity and less than 1% of all births in 
developed countries are very premature, and, second, 
that treatment effects may be subtle. Individual 
trials, with close cooperation among the trial groups, 
together with planned prospective meta-analysis of 
the data, are features of the CTC’s neonatal research.
BooST II: oxygen levels for premature 
babies
An example is the BOOST-II trial, whose objective 
is to determine the best level of blood oxygen to 
aim for in very premature infants to prevent later 
disability. The precise optimal level of oxygen is still 
not known. BOOST II is one of several recent trials 
comparing a higher range of blood oxygen saturation 
level (91–95%) with a lower range (85–89%).
 Investigators for the Australasian and UK BOOST 
II trials were faced with the need for unexpected 
decisions and changes after the announcement of 
results from a similar trial, SUPPORT, in the United 
States showed slightly higher mortality in the group 
of babies on the lower level of oxygen saturation. At 
the time, three trials, in Australia, Canada and the 
UK, were continuing, using a new software algorithm 
associated with improved targeting and greater 
separation in saturations between randomised 
groups, which closely resembles algorithms used 
in many oximeters globally. After separate reviews 
of each trial, the data monitoring committees 
independently found no reason to discontinue 
recruitment. Subsequently a joint safety analysis 
of mortality at 36 weeks gestation was undertaken 
by the UK and the combined Australian and New 
Zealand data monitoring committees by pooling 
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neoPRom InteRnAtIonAL 
CoLLAboRAtIon on oxygen 
foR bAbIeS
A prospective meta-analysis of 
all five neonatal oxygen targeting 
trials, totalling approximately 
5000 patients, is planned. The 
trialists will share individual-
patient data in a formal 
association called the NeOProM 
Collaboration. Using such fine-
grained data, rather than simply 
aggregating the results of the 
trials, improves the power of the 
analysis and extends its scope 
for detailed subgroup analyses. 
The protocol for this project has 
been published (Askie et al. in 
BMC Pediatrics), and results are 
expected after completion of all 
member trials, in 2014.
InIS trial’s new evidence will spare sick babies an 
unnecessary treatment
Newborns are deficient in endogenous immunoglobulin and so may 
be relatively unable to fight infection. Neonatal infection may lead to 
subsequent infection, various disabilities and possibly death. Adding 
immunoglobulin to their antibiotics had been shown in meta-analyses 
of various prior trials to reduce these risks, but the trials were small and 
their quality varied. To test this question, the International Neonatal 
Immunotherapy Study (INIS) enrolled 3493 infants with neonatal 
infection (1398 in Australia or New Zealand) from 9 countries, who were 
randomly assigned to receive infusions of either immunoglobulin or 
matching placebo. 
Despite the earlier evidence, the immunoglobulin infusions were 
not effective. After 2 years, the rates of disability, death and adverse 
events were the same in the two randomised groups. Immunoglobulin 
is expensive, being obtained from human donors, and is administered 
by intravenous infusion, so this therapy is not without risk. The evidence 
from this large, well-designed and conducted trial will allow hospitals, 
doctors, and their patients to avoid unnecessary treatment.
The trial completed follow-up in 2010 and the results were published 
in the New England Journal of Medicine in 2011.
Could lactoferrin prevent anaemia, prematurity and 
neonatal sepsis?
In October, a workshop for 50 participants from India and Australia was 
held at the Postgraduate Institute for Medical Education and Research, 
Chandigarh, India, to examine the evidence for lactoferrin—a low cost 
anti-inflammatory, antioxidant, antimicrobial and iron-containing dairy 
protein—in the prevention of iron-deficiency anaemia in pregnancy 
and prevention of sepsis in newborn infants at high risk. The workshop 
was jointly funded by the Australia India Strategic Research Fund and 
the Indian Department of Biotechnology. As a result of the information 
shared, applications are planned for multicentre randomised trials to 
address these important questions.
John Simes, Lucille Sebastian, William 
tarnow-mordi, Wendy Hague, 
Lisa Askie and Alpana ghadge are 
responsible for the CtC’s contributions 
to neonatal research
neonatal collaborations
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Evidence for clinical practice and policy
michelle Cummins, mark maclean and Salma fahridin, from the clinical data management team 
(Liam murphy not shown). the data management group facilitates optimum data quality and 
accuracy for each study through developing and maintaining standards and systems
CLInICaL TRIaL oPERaTIonS
Clinical trial operations
One of the advantages the CTC brings to clinical trial operations 
is its three central cross-trial teams, in data management, site 
management and quality assurance. These are the horizontal 
functions in a matrix management structure. Together, these expert 
teams ensure that systems and processes are harmonised across all 
the CTC’s trials and bring efficiency and operational excellence to all 
the varied trials coordinated by the CTC.
Rebecca mister, head of site 
management, ensures that the 
CtC has common processes across 
all trials with respect to ethics 
and regulatory applications, site 
feasibility, intervention logistics, 
and central and on-site monitoring
Phillipa Smith and 
Karen Wilkinson, 
quality assurance 
specialists, ensure 
and promote the 
high quality of the 
CtC’s trials, through 
development of 
standard operating 
procedures, training, 
and central and on-
site audit programs
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Postgraduate course in clinical trials  
up and running
In 2011, the CTC launched its postgraduate course in clinical trials 
research offered by Sydney Medical School at the University of Sydney, 
and 23 students enrolled.
 The course responds to a need for formal qualifications among 
doctors, researchers, health care professionals, study coordinators and 
others working in clinical research. 
Students will complete the course with a solid understanding of 
research methods, clinical trials literature and the clinical trials process, 
including design, protocol development, doses of treatment, and 
statistical and ethical considerations.
Students have the option of obtaining a masters degree, a graduate 
certificate or graduate diploma or studying individual units. All teaching is 
online, including lectures, tutorials, discussion forums and supplementary 
notes, so geography is no barrier to enrolment. 
Dr Mateya Trinkaus, a medical 
oncologist from Toronto, is a 
student in the Master of Clinical 
Trials course. Mateya says:
‘This course in clinical trials 
research has complemented 
my clinical training and will 
consolidate my experience in 
research, allowing me to lead 
the design and conduct of trials 
in the future.’
bCA graduate, Dr Robin turner
 ‘The masters provided training in the application 
of statistics to public health and epidemiological 
research and broadened the statistics skills I had 
gained during my PhD. I found the courses to 
be well designed and enjoyed being taught by 
leaders in the field across a range of universities. 
‘I am now a research fellow in Biostatistics in the 
Screening and Test Evaluation Program at the 
Sydney School of Public Health. The skills learnt 
during the masters have been essential to my 
ongoing research and career.’
Postgraduate courses in 
biostatistics
The Biostatistics Collaboration 
of Australia’s postgraduate 
coursework program is serving the 
need for qualified biostatisticians 
in Australia and elsewhere. The 
program is run by a consortium 
of Australian universities and 
administered from the CTC’s 
premises. 
www.bca.edu.au
EDUCaTIon
 NHMRC CLINICAL TRIALS CENTRE: 2011 RESEARCH REPORT 21
EDUCaTIon METHoDoLoGY 
Methodology: research and biostatistics outreach
Statistical predictions of risk
ComPutAtIonAL metHoDS In ePIDemIoLogy
Statistical modelling to assess the risk of clinical events is an important 
area of epidemiology. Models are used to identify individuals at risk and 
to guide interventions for reducing risk. Some risk factors are additive, but 
some are multiplicative, making the calculations complex. Biostatisticians 
at the CTC and Macquarie University have developed a model accounting 
for this complexity based on stratified additive Poisson regression. The 
model was applied to heart attacks in a large clinical trial. Results were 
published in Computational Statistics and Data Analysis.
eARLy SPReAD of enDometRIAL CAnCeR
In the LACE trial, a method of multiple cross-validation analysis was used to find a level of the cancer 
biomarker, CA-125, that would predict early spread of endometrial cancer. A cut-off level of 30 U/mL 
identified a group of patients with an increased risk. Patients with high CA-125 thus appear to have a 
one in three risk that the cancer has spread, but if the CA-125 is normal, the chance that the endometrial 
cancer is limited to the uterus is over 85%. CA-125 measurement may be a useful investigation in 
comprehensive surgical staging in the management of apparent early-stage endometrial cancer. 
val gebski became an 
honorary fellow of the Royal 
Australian and new Zealand 
College of Radiologists in 
october 2011
Macquarie University and CTC have now formally joined forces and 
obtained funding to build a cutting-edge methodological research 
program. This will leverage the expertise of both teams of biostatisticians 
and enable the group to undertake more ambitious projects.
The CTC biostatisticians undertake methodological research to 
advance the design and conduct of clinical trials, particularly in methods 
of analysis of repeated measures and time-to-event outcomes with 
competing risks, systematic review methods, methods for combining 
quality-of-life outcomes with efficacy measures and combining evidence 
using prospective meta-analysis. 
As well, responsibility for sound design and data analysis in the CTC’s 
trials generally falls to the biostatisticians, who work in collaboration with 
clinicians and others to maintain the high quality of this research. This 
expertise means that triallists working with the CTC are reassured that 
optimal study designs and state-of-the art analysis methods underpin 
their research. 
In 2011, members of the biostatistics group were co-authors on 
over 50 journal articles and 70 peer-
reviewed conference presentations. 
Christopher brown, research fellow 
in biostatistics
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Collaboration between the University of Sydney and the University of 
amsterdam on evaluation of medical tests
Clinical trials are designed to measure treatment effects, but they also provide valuable information to 
improve our understanding of the biology and natural history of disease. CTC epidemiologists Sally Lord and 
Lukas Staub explore how trial data can be used to improve the classification of disease to guide treatment 
decisions. This work has important implications for medical testing. 
Their recent study was done in collaboration with world leaders in the field of medical test research, 
Professor Les Irwig from the Screening and Test Evaluation Program (STEP), School of Public Health, 
University of Sydney, and Professor Patrick Bossuyt from the Biomarker and Test Evaluation (BiTE) research 
program at the University of Amsterdam. They published a paper in the BMJ which explains how information 
from clinical trials can be used to improve the design and interpretation of test accuracy studies.
When a test is used to guide treatment decisions, studies measuring its accuracy in distinguishing trial-
defined classifications of disease will provide clinicians with more relevant information than traditional 
measures of test accuracy for detecting the presence of all disease.
Development and evaluation of medical tests to guide personalised treatment decisions is a challenging 
new field that requires the integration of clinical trials research, medical test research, clinical expertise, and 
patient and community values. The 
advantage of this collaborative effort is 
to be able to share ideas, perspectives 
and skills with leading researchers 
working in complementary fields.
A new test is worthwhile if it detects  
diseases that will benefit from treatment  
(reprinted from BMJ, with permission)
MONITORNO ACTION TREAT
 Disease that will benefit from treatment
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EVIDEnCE FoR CLInICaL PRaCTICE anD PoLICY
Reviews of new procedures and technologies considered for public funding
In Australia, new medical procedures and technologies are funded by the taxpayer on the basis of evidence 
that they are safe, effective and cost-effective. Decisions are made by the Minister for Health and Ageing, 
advised by the Medical Services Advisory Committee (MSAC). 
A team at the CTC takes part in systematically reviewing the evidence for some of these new procedures 
and preparing reports for the committee. The evaluators are supported by an expert advisory group 
comprising clinical experts nominated by the department, and MSAC representatives. MSAC makes a 
recommendation to the Minister on the basis of the report.
The Department of Health and Ageing recently committed to a new open, transparent and integrated 
system guiding how Medicare funding decisions are made, This systemrequires decision analytic protocols 
that define the decision options or questions that agreement to fund will be based on. The evaluation team 
at the CTC was active throughout 2011 in developing and completing such protocols across a wide range of 
technologies. Clinical experts are nominated by the department and the evaluation team consult widely with 
these experts during the development of each protocol.
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the CtC’s systematic reviews and health technology assessment team: Sally Lord, toby gould, Samara Lewis, Henry Ko, Lisa 
Askie, Lukas Staub, melina Willson, William ooi, Kylie Hunter, fergus tai, thuyen vu
Cochrane Collaboration
The Cochrane Collaboration is an international organisation of more than 
28 000 health care professionals, practising physicians, researchers and 
consumers. 
The collaboration aims to provide high-quality information about the 
effectiveness of health care interventions. They search for research evidence, 
formally appraise it and publish the results as Cochrane (systematic) reviews. 
The CTC is the home of: 1. the Cochrane Breast Cancer Review Group, which 
coordinates, edits and facilitates the publication of breast cancer reviews; 
and 2. the Prospective Meta-Analysis Methods Group, an expert group for 
methodological development and advice. 
Interest in undertaking Cochrane reviews is generated at the annual 
Cochrane Colloquia, through networks of editors and authors, and through 
the Cochrane Centres. 
When a topic in breast cancer is accepted, the CTC’s Cochrane group 
works with the author team by helping to flesh out their initial proposal 
and providing specialised advice (such as clinical, statistical and consumer 
contributions) at the conceptualisation phase and at protocol and review 
stages. New Cochrane topics registered with the group reflect the diversity of authors: they are from many 
countries including Austria, Brazil, Canada, China, Italy and the UK. Recently appointed editors have come from 
the UK, USA and Italy.
Depending on their knowledge and experience, some author groups may require more support than others. 
One aim of the team at the CTC is to help new authors gain the appropriate skill set in developing Cochrane 
reviews so that they are interested in continuing with other Cochrane projects, and in general, building up the 
levels of expertise.
In 2011, the Cochrane Breast Cancer Group facilitated the publication of 7 protocols, 2 reviews, 3 review 
updates and 4 amended reviews for the Cochrane Library and received input from the Cochrane Methods Group. 
Chemotherapy alone versus endocrine
therapy alone for metastatic breast cancer
(Review)
Wilcken N, Hornbuckle J, Ghersi D
This is a reprint of a Cochrane review, prepared and 
maintained by The Cochrane Collaboration and
published in The Cochrane Library 2011, Issue 7
http://www.thecochranelibrary.com
the Cochrane breast Cancer Review 
group contributed to publication 
of this review on breast cancer 
treatment in 2011
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anZCTR: a national resource
The Australian New Zealand Clinical Trials Registry (ANZCTR), administered from the CTC, is a public, searchable 
online database that provides information on trials being conducted in Australia, New Zealand and some other 
countries. The average number of trials registered each year has increased steadily since 2006; now 6065 trials 
are registered.
The ANZCTR, together with other international trials registries, ensures that all relevant evidence can be 
accessed in determining best practice in health care. The ANZCTR can also help improve the efficiency and value 
of clinical trials research undertaken in Australia by helping improve trial participation and planning new trials in 
priority areas. 
The ANZCTR is also a resource for research to underpin policy decisions. For example, a study by researchers 
from the University of Sydney (including the CTC) published in the Medical Journal of Australia showed that in 
2009, there was significant variation in the number of trials according to the type of cancer, with some cancers 
being underrepresented relative to their burden of disease; for example, 7% of cancer trials were in lung cancer, 
even though lung cancer, of all cancers, is responsible for the greatest burden of disease. 
 > 1 000 trials (Australia)
 100–999 trials 
     (Brazil, NZ and US)
 10–99 trials (99 countries)
 <10 trials (65 countries)
 0
AnZCtR: countries of recruitment
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Health economics is an important aspect of today’s 
clinical research
In a tight fiscal environment, it is vital that we capture the financial costs 
and benefits of implementing new medical treatments. These costs and 
benefits may go beyond those in the health care system. There are often 
impacts on areas such as productivity, the costs of providing care, and flow-
on costs to the tax and welfare systems. Taking a cross-portfolio approach 
by including these societal costs leads to more-complete assessments and 
thus more efficient allocation of resources in the health system. 
The health economics team, with their national collaborators, are 
developing large-scale microsimulation models to analyse national 
productivity losses and the associated economic impacts of chronic 
conditions leading to early retirement. They are providing critical evidence 
about the cross-system influences of health interventions.
In collaboration with NATSEM (University of Canberra) and the Sydney 
School of Public Health (University of Sydney), the health economics group 
pioneered the development of Health&WealthMOD, a microsimulation 
model of the economic effects of premature retirement due to illness 
and their costs for individuals and government (funded by an Australian 
Research Council linkage grant with Pfizer Australia as an industry partner).
This work has placed Australia at the forefront of this emerging field, which 
is fundamental to ensuring that health-care funding is sustainable, families 
have adequate income and labour force participation is maximised. 
The University of Queensland has joined the collaboration (funded by 
another ARC linkage grant with Pfizer Australia) to extend the work to a 
new microsimulation model for projecting eonomic impacts up to the year 
2030. This model captures important trends, such as the rapid rise in the 
prevalence of diabetes. The findings from these studies have been published 
in highly regarded journals including the British Journal of Psychiatry, Pain, 
the International Journal of Cardiology and Spine.
Whether publicly or privately funded, advances in health care must be 
shown to be affordable as well as effective. 
Economic evaluations are an important 
aspect of assessments of new treatments and 
technologies, including the CTC’s trials and 
systematic reviews of evidence. The CTC relies 
on its health economics team to establish 
whether effective new treatments are also value 
for money.
Deborah Schofield, professor, and 
chair of health economics
Hannah verry and Rupendra 
Shrestha, health economists
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The CTC works with organisations around the world in collaborations that lead to better health outcomes in 
Australia and internationally. New collaborations are continually sought and then consolidated in research 
projects benefiting the health of Australians and others. 
gRouP nAtuRe of gRouP CtC ACtIvIty
australasian Gastro-Intestinal Trials Group 
(aGITG)
Collaborative group for gastrointestinal cancer trials: australia, new 
Zealand
International collaborations: Cancer Clinical Trials Unit Scotland (CaCTUS), 
Eastern Cooperative oncology Group (ECoG), European organisation for 
Research and Treatment of Cancer (EoRTC) , European Study Group for 
Pancreatic Cancer (ESPaC) , Groupe Coopérateur Multidisciplinarie en 
oncologie (GERCoR), national Cancer Institute of Canada Clinical Trials 
Group (nCIC CTG) , national Surgical adjuvant Breast and Bowel Project 
(nSaBP), Medical Research Council (MRC), oxford Clinical Trials office, 
oxford University (oCTo) , Pan-European Trials in alimentary Tract Cancer 
(PETaCC)
Coordinating centre
australasian Lung Cancer Trials Group 
(aLTG)
Collaborative group for lung cancer trials: australia, new Zealand Coordinating centre
International collaborations: nVaLT (netherlands), nCIC CTG (Canada)
australasian Society of Thrombosis and 
Haemostasis
Professional group undertaking thrombosis trials: australia, new Zealand Coordinating centre
australia new Zealand Gynaecological 
oncology Group (anZGoG)
Collaborative group for gynaecological cancer trials: australia, new 
Zealand
International collaborations: Dutch Gynaecologic oncology Group 
(DGoC), Group d’Investigateurs nationaux pour l’Etude des Cancers 
ovariens (GInECo), Gynecological Cancer Intergroup (GCIG), International 
Gynaecological Cancer Intergroup (IGCI), Gynecologic oncology Group 
(GoG), Medical Research Council (MRC), Scottish Gynaecologic Cancer 
Trials Group (SGCTG)
Coordinating centre
australian and new Zealand Urogenital 
and Prostate Clinical Trials Group (anZUP)
Collaborative group for cancer of the genitourinary system: australia, new 
Zealand. 
International collaborations: Cancer Research UK (CRUK), European 
organisation for Research and Treatment of Cancer (EoRTC), Groupe 
Coopérateur Multidisciplinarie en oncologie (GERCoR),Institute of Cancer 
Research (ICR), national Cancer Research Institute (nCRI), Swedish & 
norwegian Testicular Cancer Project (SWEnoTECa), and Wales Cancer 
Trials Unit (WCTU)
Coordinating centre
australian new Zealand Breast Cancer 
Trials Group (anZ BCTG)
Collaborative group for breast cancer trials: australia, new Zealand
International collaborations: International Breast Cancer Study Group 
(IBCSG), Breast International Group (BIG), International Breast Cancer 
Intervention Study (IBIS)
Statistical centre for group, 
including randomisation
australian new Zealand Clinical Trials 
Registry (anZCTR)
national register of clinical trials: australia, new Zealand and international Coordinating centre
Biostatistics Collaboration of australia Universities undertaking postgraduate education in biostatistics: australia Coordinating centre
Cholesterol Treatment Trialists’ 
Collaboration (CTTC)
Investigators of cholesterol treatment trials: australia, new Zealand, 
United Kingdom, United States, Italy
Coordination of meta-analyses 
in heart disease
Clinical Trial Development Unit (CTDU) Partnership with the Centre for Biostatistics and Clinical Trials, Peter 
MacCallum Cancer Institute: australia
Trial operation and statistical 
support for cancer trials
Cochrane Collaboration Breast Cancer 
Group
Collaborative group undertaking systematic reviews of trial evidence: 
international
Editoral base
Cochrane Prospective Meta-analysis 
Methods Group
Collaborative group undertaking systematic reviews of trial evidence: 
international
Coordinating centre
Cooperative Trials Group for neuro-
oncology (CoGno)
Collaborative group for brain cancer trials: australia Coordinating centre
Early Prevention of obesity in Children 
(EPoCH) collaboration
Prospective meta-analysis collaboration: international Data coordination centre
CoLLaBoRaTIonS
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gRouP nAtuRe of gRouP CtC ACtIvIty
European organisation for Research and 
Treatment of Cancer (EoRTC)
International collaborative group Collaborator through australian 
groups
Fenofibrate and Event-Lowering in 
Diabetes (FIELD) Study Investigators
Collaborative group for FIELD diabetes trial genetic, molecular and follow-
up substudies: australia, new Zealand, Finland, Germany
Coordinating centre
InSPIRE Meta-analysis: aSPIRE and WaRFaSa (Italy) Member
International neonatal Immunotherapy 
Study (InIS) Group
Collaborative group for InIS trial: australia, new Zealand, Europe, 
argentina
Regional coordinating centre
Long-term Intervention with Pravastatin in 
Ischaemic Disease (LIPID) Study Group
Collaborative group for LIPID cholesterol-lowering trial genetic, molecular 
and follow-up substudies: australia, new Zealand, Germany
Coordinating centre
Medical Services advisory Committee 
(MSaC) and Department of Health and 
ageing
Government: australia Provide assessments of new 
technologies and other research 
services
Menzies Research Institute and Charles 
Darwin University
Research institution: australia Collaborator 
Meta-analysis collaboration (aMICaBLE) Meta-analysis collaboration: international Collaborator
Meta-analysis of Preterm Patients 
on Inhaled nitric oxide (MaPPino ) 
collaboration
Meta-analysis collaboration: international Data coordination centre
Heart Foundation nongovernment organisation: australia Cardiovascular research
national Perinatal Epidemiology Unit 
(nPEU), University of oxford
Research institution: UK Collaborator on the InIS 
neonatal trial
neonatal oxygenation Prospective Meta-
analysis (neoProM) collaboration
Prospective meta-analysis collaboration: international Coordinating centre
nSW Cancer Council Cancer Epidemiology Research Unit Collaborator
nSW Cooperative oncology Group 
(nSWoG)
Collaborative group: new South Wales Coordinating centre
Perinatal antiplatelet Review of 
International Studies (PaRIS) collaboration
Meta-analysis collaboration:international Co-coordinating centre
Prenatal repeat corticosteroid international 
individual-patient-data study group: 
assessing the effects using the best level of 
evidence (PRECISE) collaboration
Meta-analysis collaboration: international Collaborator
Prevention of Ventilator Induced Lung 
Injury Collaborative Study Group (PreVILIG) 
Meta-analysis collaboration: international Data coordination centre
Primary Care Cancer Trials Group (PC4) Collaborative group: australia Collaborator
Primary Coronary angioplasty versus 
Thrombolysis (PCaT)
Meta-analysis collaboration: international Co-coordinating centre
Prospective Pravastatin Pooling (PPP) 
project 
Collaborative group: international Coordinating centre
Royal australasian College of Surgeons 
(RaCS)
Professional society undertaking trials of surgery: australia and new 
Zealand
Coordinating the SnaC trials in 
breast cancer
Sydney Catalyst Consortium for translational research in cancer Collaborator
Trans-Tasman Radiation oncology Group 
(TRoG)
Collaborative group: australia and new Zealand Collaborator
Star Child Health Meta-analysis collaboration: international Member
VIGoUR group Collaborative group for trials in heart disease: 40 countries VIGoUR leader
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neonAtAL DISoRDeRS
Current trials
aPTS: australian placental transfusion study neonates born before 30 weeks’ gestation  1600 101
trials in follow-up
BooST II: Benefits of oxygen saturation targeting neonates born before 28 weeks’ gestation  1200 1135
CARDIovASCuLAR DISoRDeRS
Pending trials
REMoVaL: Effects of metformin added to insulin on atheroma 
progression 
University of Glasgo and NHS-led, and CTC trial
adults with type 1 diabetes at risk of 
cardiovascular disease
90 (anZ):  
500 (international)
trials in follow-up
aSPIRE: aspirin to prevent recurrent venous thromboembolism People who have had 6 months of treatment 
with warfarin for a venous thromboembolism
 1200 (international) 689 (australasia); 
722 (international); 
1225 (InSPIRE 
meta-analysis)
FIELD: Fenofibrate intervention and event lowering in diabetes Patients with type 2 diabetes 8000 9795
LIPID: Long-term intervention with pravastatin in ischaemic 
disease
Patients with a history of coronary heart 
disease
9000 9014
bReASt CAnCeR (CoLLAboRAtIng WItH RACS)
Current trials
SnaC 2: Multicentre randomised trial of sentinel node biopsy 
versus axillary clearance
RACS and CTC study
Women with operable breast cancer, stratified 
by various factors, including age and tumour 
size
 1012 218
trials in follow-up
SnaC 1: Sentinel node biopsy versus axillary clearance 
RACS and CTC study
Women with operable breast cancer, stratified 
by various factors, including age and tumour 
size
1000 1088
gAStRoInteStInAL CAnCeR (CoLLAboRAtIng WItH AgItg)
Pending trials
GaP: Phase 2 study of gemcitabine and naB-paclitaxel
AGITG and CTC study
Patients with resectable pancreas cancer 50
ICECREaM: Irinotecan Cetuximab Evaluation and Cetuximab 
Response Evaluation among Mutants
AGITG and CTC study
Patients with Kras-WT metastatic colorectal 
carcinoma or a G13D mutation
100
IMPaCT: Phase 2 trial using genomic sequencing and protein 
expression to direct first-line treatment 
Garvan, AGITG and CTC study
Patients with metastatic pancreatic cancer 90
InTEGRaTE: Phase 2 trial comparing regorafenib and placebo
AGITG and CTC-led international study
Patients with advanced oesophagogastric 
cancer
150
TaCTIC: Phase 2 trial of panitumumab, cisplatin and 
gemcitabine 
AGITG and CTC study
Patients with biliary tract cancer 45
Current trials
a La CaRT: australian phase III randomised trial of laparascopy-
assisted resection compared with open resection
AGITG and CTC study
Patients with primary rectal cancer 470 54
aTTaCHE: Timing of surgery and adjuvant chemotherapy for 
hepatic colorectal metastases
AGITG and CTC study
Patients with confirmed resectable liver 
metastases and no other disease
200 1
DoCToR: Phase 2 trial of preoperative cisplatin, 5-fluorouracil 
and docetaxel with or without radiotherapy for oesophageal 
cancer
AGITG and CTC study
Patients with resectable adenocarcinoma of the 
oesophagus not responsive to chemotherapy
150 35
CURREnT CTC TRIaLS
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LaP07: Randomised multicentre phase III study of gemcitabine 
with or without chemoradiotherapy and with or without 
erlotinib for pancreatic cancer
GERCOR-led, AGITG and CTC study
Patients with locally advanced adenocarcinoma 
of the pancreas
60 (anZ);  
900 (international)
26 (anZ);  
423 (international)
Pan1: Phase II study evaluating potential predictive 
biomarkers in treatment of locally advanced and metastatic 
pancreatic cancer 
AGITG and CTC study
Patients with confirmed metastatic pancreatic 
adenocarcinoma
80
REGISTER: Multicentre phase II study of risk evaluation in GIST 
with selective therapy escalation for response
AGITG and CTC study
Patients with gastrointestinal stromal tumour 
not suitable for curative surgery
80 44
SCoT: Short-course oncology therapy, a study of adjuvant 
chemotherapy in colorectal cancer
MRC-led, AGITG and CTC study
Patients with fully resected stage III colorectal 
cancer
225 (anZ):  
9500 (international)
89 (anZ):  
2827 (international)
ToP GEaR: Randomised phase II–III trial of preoperative 
chemoradiotherapy versus preoperative chemotherapy for 
gastric cancer
AGITG and CTC study
Patients with resectable gastric cancer suitable 
for these treatments
120 (stage 1);  
632 (stage 2)
34
trials in follow-up
advanced GIST: Relation between dose and clinical activity of 
imatinib mesylate (aG0102, EoRTC 62005)
EORTC-led, AGITG and CTC study
Patients with unresectable or metastatic 
malignant gastrointestinal stromal tumours 
(GIST) expressing KIT receptor
80 (anZ):  
600 (international)
116 (anZ);  
946 (international)
aTTaX 3: Phase 2 trial of docetaxel, cisplatin and 
fluoropyrimidine with or without panitumumab for 
oesophagogastric cancer (aG0607oG)
AGITG and CTC study
Patients with metastatic or locally recurrent 
oesophagogastric cancer
100 77
C07: 5-fluorouracil plus leucovorin compared with oxaliplatin 
with 5-fluorouracil + leucovorin for stages II and III carcinoma 
of the colon
NSABP-led, AGITG and CTC study
Patients with resected stage II or stage III colon 
carcinoma
150 134
Co.20: Phase III study of BMS-582664 with cetuximab versus 
placebo with cetuximab
NCIC CTG-led, AGITG and CTC study
Patients with metastatic colorectal carcinoma 
previously treated with combination 
chemotherapy
370 (anZ);  
750 (international)
416 (anZ);  
686 (international)
EoRTC liver metastases: oxaliplatin, 5-fluorouracil and 
leucovorin versus surgery for resectable colorectal cancer liver 
metastases (EoRTC 40983)
EORTC-led, AGITG and CTC study
Patients with colorectal cancer with resectable 
liver metastases
330 (international) 35 (anZ);  
364 (international)
PETaCC 6: addition of capecitabine to preoperative 
oxaliplatin chemoradiotherapy and postoperative oxaliplatin 
chemotherapy for rectal cancer (aG0707R)
EORTC (PETACC)-led, AGITG and CTC study
Patients with locally advanced rectal cancer 135 (anZ);  
1090 (international)
127 (anZ);  
1094 
(international)
Quasar 2: Phase III study of capecitabine and bevacizumab as 
adjuvant treatment of colorectal cancer (aG0107CR)
OCTO-led, AGITG and CTC study
Patients with colon cancer treated by surgery 120 (anZ);  
1892 (international)
219 (anZ);  
1952 (international)
gynAeCoLogICAL CAnCeR (CoLLAboRAtIng WItH AnZgog)
Pending trials
anZGoG 1013: Phase I–II BnC105P combination study 
ANZGOG study
Women with partly platinum-sensitive ovarian 
cancer in first or second relapse
134
(international)
PaRaGon: Phase II study of anastrozole in  
gynaecological cancers
MRC, ANZGOG and CTC-led international study
Women with potentially hormone-responsive 
gynaecological cancers
 100 (anZ)
Current trials
PoRTEC 3: Chemo radiation and adjuvant chemotherapy 
compared with with pelvic radiation alone in high-risk 
endometrial carcinoma
GCIG-led, ANZGOG and CTC study
Women with advanced endometrial carcinoma  200 (anZ);  
600 (international)
89 (anZ);  
499 (international)
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outback: Phase III trial of addition of adjuvant chemotherapy 
to standard chemoradiation as primary treatment for cervical 
cancer
ANZGOG and CTC-led international study
Women with locally advanced cervical cancer  780 21 (anZ);  
28 international
Symptom benefit: does palliative chemotherapy improve 
symptoms in women with recurrent ovarian cancer? (anZGoG 
1103)
ANZGOG and PoCoG study
Women with platinum-resistant or refractory 
ovarian cancer
800 95
trials in follow-up
TRIPoD: Phase II trial of intraperitoneal chemotherapy 
(anZGoG 0601)
ANZGOG and CTC study
Women with ovarian and related cancers 35–100 39
ICon 6: Safety and efficacy of cediranib in combination with 
standard chemotherapy
MRC-led, ANZGOG and CTC study
Women with with platinum-sensitive relapsed 
ovarian cancer
400 (international) 17 (anZ); 486 
(international)
ICon 7: Randomised trial of adding bevacizumab to standard 
chemotherapy
MRC-led, ANZGOG and CTC
Women with epithelial ovarian cancer who had 
not received systemic antitumour therapy
100 76
SCoTRoC 4: Multicentre trial of carboplatin flat dosing vs 
intrapatient dose escalation in first-line chemotherapy 
SGCTG-led, ANZGOG and CTC
Women with ovarian, fallopian tube or 
peritoneal carcinoma who are unsuitable for 
platinum–taxane therapy
150 (anZ);  
1300 (international)
64 (anZ); 937 
(international)
Prospective study of risk-reducing salpingo-oophorectomy and 
longitudinal Ca-125 screening (GoG 199)
GOG-led, ANZGOG and CTC
Women aged >30 at genetic risk of ovarian 
cancer
250 83
genItouRInARy CAnCeR (CoLLAboRAtIng WItH AnZuP)
Current trials
aprepitant for germ cell chemotherapy: 7-day aprepitant 
schedule to prevent chemotherapy-induced nausea and 
vomiting (anZGCTG 0801)
ANZUP and CTC study
Patients receiving cisplatin-based 
chemotherapy for germ cell tumours
 50 50
Chemo & cognition: Cognitive function and treatment for 
testicular cancer (anZGCTG 0106)
ANZUP and CTC study
Patients being treated and followed up for 
testicular cancer
154 141
Eversun: Phase II trial of everolimus alternating with sunitinib 
for renal cell carcinoma (anZUP 0901)
ANZUP and CTC study
Patients starting first-line systemic therapy for 
advanced renal cell carcinoma
55 38
SoRCE: adjuvant sorafenib for renal cell carcinoma (RE 05)
MRC-led, ANZUP and CTC study
Patients with resected renal cell carcinoma at 
intermediate or high risk of relapse
 250 (anZ);  
1656 (international)
88 (anZ); 901 
(international)
trials in follow-up
accelerated BEP: feasibility study of accelerated BEP as first-
line chemotherapy for advanced germ cell tumours (anZGCTG 
0206, anZGoG 0603)
ANZUP, ANZGOG and CTC study
Patients with intermediate and poor-risk 
advanced germ-cell tumours (and selected 
good-risk tumours)
 25 45
Lung CAnCeR (CoLLAboRAtIng WItH ALtg)
Current trials
BR.26: Phase III trial of PF-804 in patients with incurable, non-
small-cell lung cancer (aLTG 09/002)
NCIC-led, ALTG and CTC study
Patients with stage IIIB or IV non-small-cell 
lung cancer
180 65
nITRo: phase III multicentre trial of adding nitroglycerine 
to first-line chemotherapy for advanced non-small-cell lung 
cancer (aLTG 06/003)
ALTG and CTC study
Patients with advanced non-small-cell lung 
cancer
 500 202
trials in follow-up
B2P2M2: phase II trial of BnC105P as second-line 
chemotherapy for pleural mesothelioma (aLTG 09/004) ALTG 
and CTC study
Patients with pleural mesothelioma which has 
progressed after pemetrexed and platinum 
chemotherapy
 60 6
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BR.29: Cediranib versus placebo for patients receiving 
paclitaxel and carboplatin for non-small-cell lung cancer (aLTG 
09/001)
NCIC CTG-led, ALTG and CTC study
Patients with stage IIIB or IV non-small-cell 
lung cancer
100 75
bRAIn CAnCeR (CoLLAboRAtIng WItH Cogno)
Pending trials
Phase II study of acetazolamide plus dexamethasone versus 
dexamethasone for cerebral oedema in high-grade glioma 
COGNO and CTC study
Patients with high-grade glioma requiring 
new dexamethasone or dose increase due to 
progressive or recurrent disease
 86
Phase II study of psycho-educational intervention in patients 
with primary brain tumour
PoCoG-led and COGNO study
Patients with confirmed primary brain tumours  60
Current trials
Cabaret: phase II study of carboplatin and bevacizumab in for 
glioblastoma multiforme
COGNO and CTC study
Patients with recurrent grade IV glioblastoma 
multiforme following radiotherapy and 
temozolomide chemotherapy
 120 86
CaTnon: Phase III trial of concurrent and adjuvant 
temozolomide chemotherapy for anaplastic glioma (EoRTC 
26053-22054)
EORTC-led COGNO and CTC study
Patients with non-1p/19q- deleted anaplastic 
glioma
 100 (anZ);  
748 (international)
31
Phase III trial of temozolomide and short-course radiation 
versus radiation alone (TRoG 08.02)
COGNO, TROG and CTC study
Elderly patients with new glioblastoma 
multiforme
100 (anZ);  
500 (international)
41 (anZ); 251 
(International)
SEED: Self-reported evaluation of the adverse effects of 
dexamethasone
COGNO and CTC study
Patients with brain tumours or brain 
metastases or advanced cancer using steroids
50 patients,  
50 caregivers
13
trials in follow-up
LGG: Phase III study of primary chemotherapy with 
temozolomide versus radiotherapy (TRoG 06.01, EoRTC 
22033-26033)
EORTC, COGNO, TROG and CTC study
Patients with low-grade glioma, stratified for 
genetic 1p loss
100 (anZ);  
466 (international)
36 (anZ); 466 
(international)
CTC’s research funding
 NHMRC
 Cancer Australia, 
      Cancer Institute 
      and cancer councils
 Other public funding
 Pharmaceutical industry
 Other
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Rebecca Mister
Aspirin to Prevent Recurrent Venous 
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